

# **Analysis of Oncology Deals**

## Trends in Deal Structures and Valuations

Dr Danya Morton-Holmes and Nick Fyson  
with members of PharmaVentures Corporate Advisory

Copyright © 2009 PharmaVentures Ltd

Published by PharmaDeals, Imprint of PharmaVentures Ltd  
Florey House, Oxford Science Park, Oxford, OX4 4GP, UK  
[www.pharmaventures.com](http://www.pharmaventures.com)

# Contents

1		5	
<b>Introduction to oncology</b> .....	9	<b>Oncology deals by territory</b> .....	34
1.1 Cancer.....	9	5.1 Analysis of oncology deals by territory.....	34
1.2 Incidence and mortality.....	9	5.2 Year on year analysis of oncology deals by territory.....	35
1.3 Disease impact and economic burden.....	10		
1.4 Market size.....	10	6	
1.5 Market trends.....	11	<b>Oncology deals by product type</b> .....	37
1.6 Current therapies.....	13	6.1 Oncology deals by product type (August 2008 to July 2009).....	37
1.6.1 Approaches used.....	13	6.2 Diagnostics.....	38
1.6.2 Drug treatment.....	13	6.3 Vaccines.....	39
1.7 Future treatments – products in development.....	15	6.4 Oncology deals by product type (August 2008 to July 2009).....	40
1.8 Key players.....	16		
2		7	
<b>Overall trends in oncology deals</b> .....	17	<b>Analysis of royalties in oncology deals</b> .....	42
2.1 Comparison with other therapy areas.....	17	7.1 Overview.....	42
2.2 Total number of oncology deals.....	18	7.2 Case studies.....	44
2.3 Total value of oncology deals.....	19	7.2.1 Indevus Pharmaceuticals Inc and Valera Pharmaceuticals Inc.....	44
3		7.2.2 Zila Professional Pharmaceuticals and Trylon Corporation.....	45
<b>Analysis of oncology deals by deal type</b> ..	22	7.2.3 Ipsen and Tercica.....	46
3.1 Types of oncology deals.....	22	7.2.4 Pharmion Corp and GPC Biotech AG.....	47
3.2 Year on year analysis by deal type.....	24	7.2.5 pSivida and Beijing Med-Pharm.....	48
3.3 Deal type by value.....	26	7.2.6 Seattle Genetics and Genentech.....	49
4		7.3 Conclusions.....	49
<b>Oncology deals by stage of development</b> .....	28		
4.1 Number of oncology deals by stage of development.....	28		
4.2 Type of deal by stage of development.....	29		
4.3 Year on year analysis of oncology deals by stage of development.....	30		
4.4 Value of oncology deals by stage of development.....	31		
4.5 Case studies.....	33		

8		11.3 Phase II.....	84
	<b>Key players in oncology deal making</b> .....	11.3.1 Antisoma and Novartis .....	84
8.1	Analysis of the top ten dealmakers	11.3.2 Amgen and Takeda .....	85
	– companies.....	11.3.3 Micromet and Serono.....	86
8.1.1	Roche.....	11.3.4 Celgene and GlobalImmune.....	87
8.1.2	Genentech (now part of Roche).....	11.4 Phase III.....	89
8.1.3	Merck & Co Inc .....	11.4.1 Spectrum and Allergan .....	89
8.1.4	GlaxoSmithKline.....	11.4.2 Cell Therapeutics and Novartis.....	90
8.1.5	AstraZeneca .....	11.4.3 Novelos and Mundipharma .....	92
8.1.6	Pfizer.....	11.5 Launched .....	93
8.1.7	Abbott Laboratories .....	11.5.1 Antisoma and sanofi-aventis.....	93
8.1.8	Novartis.....		
8.1.9	Bristol-Myers Squibb.....	12	
8.1.10	Takeda .....	Appendix 3	
		<b>Reference to Deals in the Report</b> .....	95
9			
	<b>Conclusions</b> .....		
10			
	Appendix 1		
	<b>Deal type by value</b> .....		
11			
	Appendix 2		
	<b>Case studies:</b>		
	<b>High value deals</b>		
	<b>by stage of development</b> .....		
11.1	Pre-clinical.....		
11.1.1	AVEO Pharmaceuticals Inc. and Schering-Plough Corp.....		
11.1.2	Micromet and Bayer Schering Pharma.....		
11.1.3	Vertex and Merck .....		
11.1.4	S*BIO and Tragara.....		
11.1.5	Array Biopharma and AstraZeneca.....		
11.2	Phase I .....		
11.2.1	ThromboGenics / BioInvent and Roche for TB-403 .....		
11.2.2	Amgen and Kyowa Hakko.....		
11.2.3	Lpath and Merck Serono .....		
11.2.4	ArQule and Roche.....		

# Tables

1	Top oncology brands 2007 .....	14
2	Top 5 oncology drugs 2014 .....	14
3	All compounds in development for oncology indications (September 2009) .....	15
4	Compounds in development for oncology (excluding those in later stage development in other therapy areas) (September 2009).....	15
5	Key players in oncology based on sales value, 2008 .....	16
6	Selected acquisition deals 2008/9 .....	24
7	Deal type by value (1997 to July 2009) .....	26
8	Deals by type and stage of development (1997 to July 2009) .....	30
9	Year on year analysis of deals by territory (1997 to July 2009) .....	35
10	Selected antibody based deals 2008 .....	40
11	Royalty rate percentages by development stage in oncology deals (1997 to July 2009) ....	43
12	Top twenty oncology dealmakers (1997 to July 2009) .....	50
13	Top twenty oncology dealmakers (2000 to July 2009) .....	51
14	Top seventeen deal making companies (2005 to July 2009) .....	53
15	Top three public institutes (2005 to July 2009) .....	53
16	Comparison of the ranking of the top oncology companies .....	54

# Figures

1	Deal intensity by therapeutic area (1997 to July 2009) .....	17	20	Marketing deal values by frequency and range (1997 to July 2009).....	69
2	Total oncology deals by year (1997 to July 2009) .....	19	21	Technology Access deal values by frequency and range (1997 to July 2009).....	69
3	Total oncology deal values (1997 to July 2009) .....	20	22	Finance deal values by frequency and range (1997 to July 2009) .....	70
4	Deal numbers and deal values excluding M&A (1997 to July 2009) .....	20	23	Manufacture deal values by frequency and range (1997 to July 2009).....	70
5	Total deals by type (1997 to July 2009).....	22			
6	Further breakdown of Collaborative/Licensing deal types (1997 to July 2009).....	23			
7	Year on year analysis of deal types showing total deal numbers per year (1997 to July 2009) .....	24			
8	Year on year analysis of deal types showing individual deal type trends year on year (1997 to July 2009) .....	25			
9	Year on year analysis of Collaborative/Licensing deal types (1997 to July 2009).....	25			
10	Value of deals by type – lower to upper quartiles (1997 to July 2009) .....	27			
11	Number of deals by stage of development (1997 to July 2009) .....	29			
12	Deals by type and stage of development (1997 to July 2009) .....	29			
13	Year on year analysis of deals by stage of development (1997 to July 2009) .....	30			
14	Average value of deals by stage of development (1997 to July 2009) .....	31			
15	Number of deals by territory (1997 to July 2009) .....	34			
16	Year on year analysis of deals by territory (1997 to July 2009) .....	35			
17	Oncology deals by product type (1997 to July 2009) .....	37			
18	Disclosed royalty rates for selected oncology deals (1997 to July 2009) .....	43			
19	Collaborative/Licensing deal values by frequency and range (1997 to July 2009) .....	68			